AI In Clinical Trials: 21 Startups Speeding Up The Drug Pipeline | #VentureCanvas

Deepashri Varadharajan | CBInsights


Bringing a new drug to market is a long and drawn-out process. A study published by the US Department of Health and Human Services identifies several reasons why, including the difficulty of recruiting the right pool of patients, high costs ($161M – $2B per drug), and lengthy study times (averaging 7.5 years).

In fact, the high cost of R&D is a frequently-cited reason for the often controversially high price of prescription drugs.


Source: AI In Clinical Trials: 21 Startups Speeding Up The Drug Pipeline